Scarica l'app Stockscreener
26.43
2.63%
-0.715
Dopo l'orario di chiusura:
26.44
0.005
+0.02%
Precedente Chiudi:
$27.15
Aprire:
$26.81
Volume 24 ore:
585.28K
Relative Volume:
0.98
Capitalizzazione di mercato:
$1.89B
Reddito:
$81.26M
Utile/perdita netta:
$-102.66M
Rapporto P/E:
-19.33
EPS:
-1.3678
Flusso di cassa netto:
$-77.62M
1 W Prestazione:
-11.59%
1M Prestazione:
+9.42%
6M Prestazione:
+3.83%
1 anno Prestazione:
+74.03%
Intervallo 1D:
$26.39
$27.04
Intervallo di 1 settimana:
$26.39
$29.99
Portata 52W:
$14.88
$31.34
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
26.43 | 1.94B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Ripresa | Wells Fargo | Equal Weight |
| 2025-10-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Zymeworks stock hits 52-week high at 30.75 USD - Investing.com
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Nigeria
ZJM stock holds near its latest trade. Zymeworks data still drives the setup - ad-hoc-news.de
Enterprise value to revenue forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME - MarketBeat
4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc. - marketbeat.com
Zymeworks stock holds near $28.27 as market cap tops $2.01 billion - ad-hoc-news.de
FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright - MarketBeat
Zymeworks shifts to revenue growth after FDA ap... - Pluang
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings - marketbeat.com
Zymeworks moves higher as Street cheers Ziihera regimen approval - Seeking Alpha
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens - Sahm
Zymeworks stock hits 52-week high at 29.81 USD By Investing.com - Investing.com South Africa
Zymeworks stock rating reiterated at Market Outperform by Citizens - Investing.com India
Zymeworks (NASDAQ:ZYME) Stock Price Up 11.4% After Analyst Upgrade - MarketBeat
Zymeworks Announces FDA Approval of Ziihera-Based Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma and $250 Million Milestone Payment from Jazz Pharmaceuticals - quiverquant.com
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - NTB Kommunikasjon
Zymeworks stock hits 52-week high at 29.81 USD - Investing.com
Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab - Yahoo Finance
Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan
Enterprise value to revenue forward of Zymeworks Inc. – SWB:ZA8 - TradingView
Zymeworks (ZYME) Session Brief: Climbs 2.69% to $25.99 in the Latest Session; Reference Levels: $24.69 and $27.29 Define the Nearby Reference Levels at the ClosePCR Spike - vinanet.vn
How Zymeworks’ Bigger Loss, Buyback and Milestones Pivot At Zymeworks (ZYME) Has Changed Its Investment Story - simplywall.st
ZYME Q2 2026 Earnings: Wider-than-Expected Loss of -$0.62 per Share Reflects Clinical-Stage InvestmentProduct Revenue Analysis - vinanet.vn
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance Australia
Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright - MarketBeat
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - Yahoo Finance
HC Wainwright Issues Negative Outlook for Zymeworks Earnings - MarketBeat
Zymeworks Announces Participation in Upcoming Investor Conferences - Macau Business
Zymeworks Inc. to Participate in Upcoming Investor Conferences in September - Quiver Quantitative
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TradingView
Theravance's Once-Daily COPD Treatment Posts $70.7M Sales - Stock Titan
Zymeworks (ZYME) Is Up 7.3% After Q2 Swing Back to Net LossesWhat's Changed - simplywall.st
Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zymeworks (ZYME) Stock Rich Valuation Meets Widening Losses - Sahm
Zymeworks Inc (ZYME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
What is HC Wainwright's Forecast for Zymeworks Q2 Earnings? - MarketBeat
Zymeworks Inc. (ZYME): Analyst Consensus and Potential 72% Upside Make This Biotech Stock Worth Watching - DirectorsTalk Interviews
Is Zymeworks Inc (ZYME) Facing Challenges After Q2 Earnings Miss? GF Score: 65/100, Revenue at $4.6M - GuruFocus
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Zymeworks Inc. Stock 12‑Month Price Target Raised to $40, Implies 73% Upside - TradingView
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Zymeworks Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Zymeworks Inc. Q2 2026: Revenue $4.6M, EPS $(0.62) — 10-Q Summary - TradingView
Zymeworks Inc. (NASDAQ: ZYME) details $250M royalty deal and Theravance bid - Stock Titan
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):